Jeb Keiper

New Capabilities

Positioning Nimbus’s AI/computational approach as a real contributor to zasocitinib’s speed from design to late-stage success

Psoriasis has been an injectable kingdom for years: shots that work great, pills that usually don't. Takeda's once-daily TYK2 pill zasocitinib just cleared Phase 3 topline hurdles—and by the next session investors responded, sending Takeda shares up as much as 4.3% in early Tokyo trading (a seven-month-high intraday jump).

Updated May 15